RNS Number : 7479Z
N4 Pharma PLC
16 January 2024

16 January 2024

N4 Pharma plc
("N4 Pharma" or the "Company")

Nanogenics Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, is pleased to provide an update on its subsidiary, Nanogenics Limited ("Nanogenics").

Nanogenics has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at Kings College, London.

Nanogenics' ECP105 product for the recovery of post-surgical treatment of Glaucoma contains a proprietary siRNA sequence to silence the fibrotic gene MRTF-B. Glaucoma patients who have failed to respond to medication need surgery to lower intraocular pressure which causes fibrosis at the surgery site. This fibrosis often leads to failure of the surgery and frequently patients have to undergo further surgery. ECP105 is intended for injection into the ocular cavity to switch off the gene responsible for the fibrosis. Unlike current off-label treatment using toxic chemotherapy drugs, ECP105 is intended for repeat use to prevent the need for further surgery.

The work involves creating and testing a novel formulation containing Nanogenics' proprietary siRNA sequence to undertake a proof of concept *in-vivo* study, to demonstrate that a single dose of its Glaucoma surgery treatment ECP105 can match the anti-fibrotic effect of current post surgical treatment using Mitomycin C, but without the cytotoxic side effects seen with this approach.

Nigel Theobald, Chief Executive Officer of the Company, commented:

"We are very excited for the potential of ECP105, which is a unique product for an unmet clinical need in the ophthalmology market. More than 75 million people worldwide are affected by Glaucoma and the total Glaucoma treatment market size in 2021 exceeded $5.5 billion and is growing. A novel product in this space alone represents a good opportunity for Nanogenics and importantly the antifibrotic siRNA sequence can also be used to investigate other fibrotic treatments for liver and lung fibrosis."

For more information please contact:

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Via N4 Pharma Investor Hub

Engage with us directly at N4 Pharma Investor Hub
Sign up at investors.n4pharma.com

To hear more, visit
https://investors.n4pharma.com/link/GyVdGr

SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Kasia Brzozowska (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44(0)20 3470 0470

Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44(0)20 3657 0050

IFC Advisory Ltd
Financial PR
Graham Herring
Zach Cohen
Tel: +44(0)20 3934 6630

About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.

N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDBAMFTMTTBBFI